GlassScriptPhysician profile
Ryszard Skulski
NPI 1083611685
$9,651.92
in general payments reported to CMS, 2019-2025
33 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $994 · 2021: $1,181 · 2022: $683 · 2023: $1,977 · 2024: $2,403 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,389 · Travel and Lodging: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.35 |
| Travel and Lodging | $439.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,113.14 | 2019-2025 | Merlin@Home, Aveir, Xience Skypoint |
| Boston Scientific Corporation | $2,067.23 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr, Ams 700 |
| Abiomed | $1,175.32 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $1,062.43 | 2019-2024 | Xarelto |
| Medtronic, INC. | $798.59 | 2021-2025 | Micra, Linq II, Symplicity G3 |
| Chiesi USA, INC. | $290.85 | 2019-2023 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $220.95 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Edwards Lifesciences Corporation | $146.89 | 2023-2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $145.07 | 2023-2025 | Evenity, Repatha |
| Novartis Pharmaceuticals Corporation | $139.91 | 2023-2024 | |
| Abbvie INC. | $125.00 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $123.49 | 2025 | |
| Intuitive Surgical, INC. | $118.53 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.60 | 2023-2025 | Lifevest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.87 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $86.61 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $74.89 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.87 | 2022-2025 | Eliquis |
| Arbor Pharmaceuticals, INC. | $68.49 | 2020-2021 | |
| Erbe USA INC | $50.00 | 2024 | |
| Pfizer INC. | $49.66 | 2025 | |
| Philips North America LLC | $43.99 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $43.91 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $40.89 | 2019 | |
| Cordis US Corp. | $34.93 | 2025 | Mynx Control |
| Cardiva Medical, INC. | $24.18 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Almatica Pharma LLC | $23.16 | 2021 | |
| Novo Nordisk INC | $21.02 | 2024 | Wegovy |
| Zoll Circulation INC | $19.07 | 2023 | Catheter, Therox Ds2 Console, Downstream Cartridge |
| Covidien LP | $16.96 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.68 | 2021 | |
| Medtronic Vascular, INC. | $15.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryszard Skulski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.